84例血管免疫母细胞性T细胞淋巴瘤临床特征与预后单中心分析
该单中心回顾性研究纳入84例经病理确诊的AITL患者,中位年龄62岁,95.2%为Ⅲ~Ⅳ期。化疗可评估61例,完全缓解率26.2%,5年OS率46.0%、PFS率38.3%。多因素分析显示年龄>60岁和浆膜腔积液是OS的独立不良预后因素。
要点
- AITL初诊多为晚期,侵袭性高、进展快、预后差。
- 年龄>60岁和浆膜腔积液是OS独立不良预后因素。
- 年龄、IPI、PIT、血红蛋白及浆膜腔积液可参考预测预后。
核心结论
- AITL是一种侵袭性高、进展快、预后差的非霍奇金淋巴瘤,初诊时多为Ⅲ~Ⅳ期。
- 治疗前年龄、IPI评分、PIT评分、血红蛋白水平及浆膜腔积液可作为评价预后的参考指标。
研究设计与样本
- 单中心回顾性分析纳入2009年7月至2018年9月福建医科大学附属协和医院经淋巴结病理及免疫组化确诊的84例AITL患者。
- 采用Log-rank检验及Cox比例风险回归模型分析影响总生存(OS)和无进展生存(PFS)的预后因素。
主要发现
- 84例患者中位年龄62岁(范围39~86岁),年龄>60岁者占52.4%,男女比例2.5∶1。
- Ann Arbor分期Ⅲ~Ⅳ期者占95.2%,伴B症状者占63.1%。
- IPI评分3~5分者占70.2%,PIT评分2~4分者占50.0%。
- 可评估疗效的61例中完全缓解/不确定的完全缓解率26.2%,部分缓解率41.0%,总体反应率67.2%。
- 61例患者5年OS率和PFS率分别为46.0%和38.3%。
关键数值与推荐
- 单因素分析显示年龄、IPI评分、PIT评分、血红蛋白水平、浆膜腔积液及是否化疗对OS有预后意义。
- 年龄>60岁、血红蛋白<110 g/L及存在浆膜腔积液是影响PFS的不良因素。
- 多因素分析显示年龄>60岁和浆膜腔积液是OS的独立不良预后因素。
临床怎么用
- 初诊AITL患者应评估年龄、IPI评分、PIT评分、血红蛋白水平及有无浆膜腔积液以分层预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: In order to clarify the clinical characteristics and prognostic factors of AITL, we performed a retrospective analysis on the AITL patients at our hospital. Methods: The clinical data of 84 AITL patients diagnosed by lymph node pathology and immunohistochemistry in the Fujian Medical University Union Hospital between July 2009 and September 2018 were collected, and the prognostic factors affecting overall survivol (OS) and progression-free surrival (PFS) were retrospectively analyzed by Log-rank test and Cox progortional hazard regression model. Results: The median age of the 84 patients was 62 y (range, 39-86 y) with 52.4% of the patients aged >60 y. The male-to-female ratio was 2.5∶1. 80 patients (95.2%) presented with advanced-stage disease, and B symptoms were observed in 53 cases (63.1%) . Fifty-nine patients (70.2%) had intermediate high and high risk as per the international prognostic index (IPI) and 42 (50.0%) had intermediate high risk as per the prognostic index for peripheral T-cell lymphoma (PIT) . The treatment response could be evaluated in 61 of the 67 patients who underwent chemotherapy. The complete remission (CR/CRu) rate was 26.2% (16/61) , and the partial response rate was 41.0% (25/61) . The 5-year OS rate and PFS rate in 61 patients was 46.0% and 38.3%, respectively. The univariate analysis showed that age, IPI score, PIT score, hemoglobin level, presence of serous effusions, and chemotherapy influenced the OS. Age >60 y, hemoglobin level <110 g/L, and presence of serous effusions were poor prognostic factors for PFS. Multivariate analysis showed that age >60 y and serous effusion were independent poor prognostic factors of OS. Conclusions: AITL is a Non-Hodgkin lymphoma with high invasion, rapid progress, and poor prognosis. The age, IPI score, PIT score, hemoglobin levels, and serous effusion can be used as reference factors for predicting the prognosis in AITL patients. 目的: 对就诊于我院的初治血管免疫母细胞性T细胞淋巴瘤(AITL)患者进行回顾性研究,探讨AITL患者的临床特征及影响预后的因素。 方法: 收集2009年7月至2018年9月就诊于福建医科大学附属协和医院,经淋巴结病理及免疫组织化学检查确诊为AITL患者的临床资料,采用Log-rank检验及Cox比例风险回归模型分析影响患者总生存(OS)期和无进展生存(PFS)期的预后因素。 结果: 纳入患者84例,中位发病年龄62(39~86)岁,年龄>60岁者44例(52.4%),男60例(71.4%),男女比例2.5∶1,Ann Arbor分期Ⅲ~Ⅳ期者80例(95.2%),伴B症状者53例(63.1%)。国际预后指数(IPI)评分0~2分者25例(29.8%),3~5分者59例(70.2%)。外周T细胞淋巴瘤预后指数(PIT)评分0~1分者42例(50.0%),2~4分者42例(50.0%)。可评估疗效的61例患者中有16例(26.2%)获得完全缓解/不确定的完全缓解,25例(41.0%)获得部分缓解,总体反应率为67.2%,5年OS率和PFS率分别为46.0%和38.3%。单因素分析显示,年龄、IPI评分、PIT评分、HGB水平、是否有浆膜腔积液、是否化疗对AITL的OS有预后意义,而年龄>60岁、HGB<110 g/L及存在浆膜腔积液是影响PFS的不良因素。多因素分析显示,年龄>60岁、有浆膜腔积液是OS的独立不良预后因素。 结论: AITL是一种侵袭性高、进展快、预后差的非霍奇金淋巴瘤,初诊时多为Ⅲ~Ⅳ期。治疗前的年龄、IPI评分、PIT评分、HGB水平及是否有浆膜腔积液可作为评价预后的参考指标。.
引用
- Li TT, Luo LT, Chen Y, et al. [Clinical characteristics and prognosis in 84 patients with angioimmunoblastic T-cell lymphoma: a single-center analysis]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33333694. doi:10.3760/cma.j.issn.0253-2727.2020.11.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。